155 related articles for article (PubMed ID: 36768739)
21. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.
Rubicz R; Zhao S; Wright JL; Coleman I; Grasso C; Geybels MS; Leonardson A; Kolb S; April C; Bibikova M; Troyer D; Lance R; Lin DW; Ostrander EA; Nelson PS; Fan JB; Feng Z; Stanford JL
Mol Oncol; 2017 Feb; 11(2):140-150. PubMed ID: 28145099
[TBL] [Abstract][Full Text] [Related]
22. Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer.
Sapre N; Hong MK; Macintyre G; Lewis H; Kowalczyk A; Costello AJ; Corcoran NM; Hovens CM
PLoS One; 2014; 9(4):e91729. PubMed ID: 24705338
[TBL] [Abstract][Full Text] [Related]
23. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
24. MiR-1273 g-3p Promotes Malignant Progression and has Prognostic Implications in Prostate Cancer.
Chang Y; Deng Q; Guan Z; Cheng Y; Sun Y
Mol Biotechnol; 2022 Jan; 64(1):17-24. PubMed ID: 34431044
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.
Martens-Uzunova ES; Jalava SE; Dits NF; van Leenders GJ; Møller S; Trapman J; Bangma CH; Litman T; Visakorpi T; Jenster G
Oncogene; 2012 Feb; 31(8):978-91. PubMed ID: 21765474
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
28. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
29. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
[TBL] [Abstract][Full Text] [Related]
30. Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells.
Laursen EB; Fredsøe J; Schmidt L; Strand SH; Kristensen H; Rasmussen AKI; Daugaard TF; Mouritzen P; Høyer S; Kristensen G; Stroomberg HV; Brasso K; Røder MA; Borre M; Sørensen KD
Am J Pathol; 2019 Dec; 189(12):2377-2388. PubMed ID: 31539518
[TBL] [Abstract][Full Text] [Related]
31. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
32. miR-425-5p as an exosomal biomarker for metastatic prostate cancer.
Rode MP; Silva AH; Cisilotto J; Rosolen D; Creczynski-Pasa TB
Cell Signal; 2021 Nov; 87():110113. PubMed ID: 34371055
[TBL] [Abstract][Full Text] [Related]
33. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
Zedan AH; Blavnsfeldt SG; Hansen TF; Nielsen BS; Marcussen N; Pleckaitis M; Osther PJS; Sørensen FB
PLoS One; 2017; 12(6):e0179113. PubMed ID: 28628624
[TBL] [Abstract][Full Text] [Related]
35. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
36. Discovery and Validation of Serum MicroRNAs as Early Diagnostic Biomarkers for Prostate Cancer in Chinese Population.
Lyu J; Zhao L; Wang F; Ji J; Cao Z; Xu H; Shi X; Zhu Y; Zhang C; Guo F; Yang B; Sun Y
Biomed Res Int; 2019; 2019():9306803. PubMed ID: 31534967
[TBL] [Abstract][Full Text] [Related]
37. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
38. Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues.
Ambrozkiewicz F; Karczmarski J; Kulecka M; Paziewska A; Cybulska M; Szymanski M; Dobruch J; Antoniewicz A; Mikula M; Ostrowski J
Biomed Res Int; 2020; 2020():9086829. PubMed ID: 32462034
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer.
Lichner Z; Fendler A; Saleh C; Nasser AN; Boles D; Al-Haddad S; Kupchak P; Dharsee M; Nuin PS; Evans KR; Jung K; Stephan C; Fleshner NE; Yousef GM
Clin Chem; 2013 Nov; 59(11):1595-603. PubMed ID: 23958847
[TBL] [Abstract][Full Text] [Related]
40. microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.
Bakkar A; Alshalalfa M; Petersen LF; Abou-Ouf H; Al-Mami A; Hegazy SA; Feng F; Alhajj R; Bijian K; Alaoui-Jamali MA; Bismar TA
Mol Biol Rep; 2016 Apr; 43(4):229-40. PubMed ID: 26907180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
